Literature DB >> 11313253

Competition between normal [674C] and mutant [674R] subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes.

E G Arias-Salgado1, N Butta, C González-Manchón, S Larrucea, M S Ayuso, R Parrilla.   

Abstract

This work aimed at investigating the function of the [C674R] mutation in GPIIb that disrupts the intramolecular 674 to 687 disulfide bridge. Individuals heterozygous for this mutation show a platelet GPIIb-IIIa content approximately 30% of normal controls, which is less than expected from one normal functioning allele. Coexpression of normal [674C]GPIIb and mutant [674R]GPIIb with normal GPIIIa produced a [674R]GPIIb concentration-dependent inhibition of surface exposure of GPIIb-IIIa complexes in Chinese hamster ovary (CHO) cells, suggesting that [674R]GPIIb interferes with the association and/or intracellular trafficking of normal subunits. Mutation of either 674C or 687C had similar effects in reducing the surface exposure of GPIIb-IIIa. However, substitution of 674C for A produced a much lesser inhibition than R, suggesting that a positive-charged residue at that position renders a less efficient subunit conformation. The mutant [674R]GPIIb but not normal GPIIb was found associated with the endoplasmic reticulum chaperone BiP in transiently transfected CHO cells. BiP was also found associated with [674R]GPIIb-IIIa heterodimers, but not with normal GPIIIa or normal heterodimers. Overexpression of BiP did not increase the surface exposure of [674R]GPIIb-IIIa complexes, indicating that its availability was not a limiting step. Platelets from the thrombasthenic patient expressing [674R]GPIIb-IIIa were found to bind soluble fibrinogen in response to physiologic agonists or dithiothreitol treatment. Thus, the [674R]GPIIb mutation leads to a retardation of the secretory pathway, most likely related to its binding to the molecular chaperone BiP, with the result of a defective number of functional GPIIb-IIIa receptors in the cell surface.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313253     DOI: 10.1182/blood.v97.9.2640

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

Review 1.  Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?

Authors:  Alan Nurden
Journal:  J Blood Med       Date:  2021-07-08

2.  Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of thirty-two Turkish patients with Glanzmann thrombasthenia: a multicenter experience

Authors:  Berkay Saraymen; Sabahattin Muhtaroğlu; Mustafa Yavuz Köker; Nazan Sarper; Emine Zengin; Canan Albayrak; Davut Albayrak; Bülent Zülfikar; Başak Koç Şenol; Esma Bentli; Semih Yılmaz; Aysun Çetin; Bülent Eser; Mustafa Çetin
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.